ACHIEVING FASTER PRODUCT LAUNCH: HOW DO YOU OBTAIN NON-REIMBURSED PHARMACEUTICAL PRICES ACROSS EUROPE?

Craddy P¹, Bailey S², Wolfram V², Foxon G² ¹Remap Consulting, Bern, Switzerland, ²Remap Consulting, Cheshire, United Kingdom




PHP55

Introduction

- Approximately one in four prescription-only medicinal products are paid out of pocket by EU patients, whereas the rest is funded by the health care system or compulsory health insurances via reimbursement procedures.¹
- For reimbursed products, the price setting process for new pharmaceutical products are clearly defined across EU markets with information being readily accessible.
- There is a lack of published information concerning the pricing processes for non-reimbursed prescription-only medicinal products.
- The objective of this research was to determine national price submission procedures across Europe required for launch and patient access for non-reimbursed prescription-only medicinal products.





- To determine markets for inclusion within this study, Organisation for Economic Co-operation and Development (OECD) pharmaceutical spend data across Europe (based on 2012 [or latest available year]) was utilized to identify the countries that account for 90% of European pharmaceutical spend.
- Only countries covered by the centralized marketing authorisation procedure of the European Medicines Agency (EMA) were included in the analysis.
- ▶ 11 countries, covered by the EMA, were found to represent 90% of European pharmaceutical spend.
- National price submission procedures for non-reimbursed prescription-only medicinal products across these 11 countries were analysed.
- Pricing authorities were contacted to obtain additional information related to price setting if ambiguities existed.

Results

National price submission procedures for non-reimbursed prescriptiononly medicinal products across 11 European countries

Price submission procedures were classified as: full price submission process;

Table 1. Price submission procedures across 11 European countries

Price level to Country be submitted

Pricing body



abridged price submission process, or no price submission (Figure 2).

Nine of the 11 countries mandate submission of pricing documents (Table 1).

- Six countries require a full price submission to the national pricing authority.
- Three countries ask for an abridged pricing submission (i.e. price notification).
- Two countries have no price submission or notification requirements.
- Negotiations with pricing bodies for non-reimbursed prescription-only products are limited, enabling manufacturers to have control over the price setting.

Figure 2. Countries grouped by price submission process

Full price submission process	Abridged price submission process		
AustriaImage: Constraint of the second s	Image: NetherlandsImage: Spain	Poland Sweden	
Greece Italy UK Full price submission required, comparable to those needed to secure the price for a reimbursed product	Authorities need to be notified about the maximum price	No price submission needed and no official price will be published. Price just communicated to wholesalers	

					available
		Austria	Ex-factory	The Federal Ministry of Health, Family and Youth (BMG)	No
	sion	Belgium	Ex-factory	Federal Public service of Economic affairs	Yes
	submission	Germany	Ex-factory	Lauer Taxe, Rote Liste	Yes
	price 3	Greece	Ex-factory	National Organization for Medicines (EOF)	Yes
	Full	Italy	Ex-factory	Italian Medicines Agency (AIFA)	Yes
		UK	Pharmacy selling price	UK Department of Health	Yes
	price submission	France	Ex-factory	L'Agence nationale de sécurité du médicament et des produits de santé (ANSM)	No
	rice sub	Netherlands	Wholesale selling price	Z index	Yes
	Abridged pi	Spain	Ex-factory	Ministerio de Sanidad Asuntos Sociales e Igualdad Subdirección de Calidad de Medicamentos	No
	o ssion	Poland	N/A	Ministry of Health	No
	No submission	Sweden	N/A	Dental and Pharmaceutical Benefits Agency (TLV)	No

Discussion and Conclusion

- The majority of countries require submission of pricing documents for nonreimbursed prescription-only medicinal products prior to product launch. As a result, the prices of these products are placed on official drug lists, which raises physician awareness of product availability.
- Typically, price submission processes are less burdensome for non-reimbursed products when compared to reimbursed products. Nevertheless, they are still time and resource intense to achieve a successful outcome.
- ▶ It is important for manufacturers to actively manage international prices, as several non-reimbursed markets require prices from other EU countries to be declared during the pricing process.
- With more freedom over prices manufacturers need to consider patient willingness to pay when determining the optimal non-reimbursed price levels.

ISPOR 21st Annual International Meeting, 21-15 May 2016, Washington, USA

- Health technology assessments for non-reimbursed prescription-only medicinal products are undertaken in some markets. This has not been included within this scope and could be a further area for research.
- Typically, time to patient access is faster for non-reimbursed prescription-only products compared to reimbursed products, but it is likely that the revenues will be lower, as patients may have lower willingness to pay.
- Whilst seeking a non-reimbursed launch price in Europe can be an optimal strategy for certain therapy areas, manufacturers should ensure such an approach optimizes revenues when compared to a reimbursed approach.

References

1. Organisation for Economic Co-operation and Development (OECD), http://stats.oecd.org/

